# Yingke Biopharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yingke-biopharmaceutical

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.yk-bio.com
- Total disclosed funding: $42M
- Latest round: Series B (Jun 1, 2023)
- Investors on record: 6

## About

Based in Taizhou, China and founded in 2011, Yingke Biopharmaceutical operates as a biopharmaceutical research and development company that focuses on the fields of energy medicine, anesthesia, oncology and other pharmaceuticals. In 2013, the company's mushroom polysaccharide API workshop passed the new version of GMP certification. Some honorable titles such as Top Ten Innovative Technology Enterprises, Jiangsu Science and Technology SMEs and National High and New Technology Enterprises have been granted to Yingke. In December 2022, its Propanol emulsion injection was approved for marketing. In June 2023, Yingke Biopharmaceutical raised over CNY 300 million in series B funding.

The company is dedicated to the research, development and application of parenteral nutrition drugs, anesthesia, oncology, highly concentrated amino acids and diagnostic kits in the pharmaceutical field. The main products are Propofol medium/long chain fatty milk injection, medium/long chain fatty milk injection C6-24, mushroom polysaccharide injection and motherwort soft capsule. Yingke Biopharmaceutical has also launched products such as the myorelaxant mikonium chloride and the analgesic meloxicam.

## Funding rounds

- Series B, Jun 1, 2023, $42M — China Life Capital, Sherpa Healthcare Partners, BCT Capital, Xinshang Investment
- Series A, Mar 21, 2016 — CMC Rongjianda Venture Investment
- Angel, Jul 17, 2015 — Huaxin Capital

## Investors

- Huaxin Capital — Angel
- CMC Rongjianda Venture Investment (https://capitalatlas.ai/funds/cmc-rongjianda-venture-investment) — Series A
- China Life Capital — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- BCT Capital (https://capitalatlas.ai/funds/bct-capital) — Series B
- Xinshang Investment (https://capitalatlas.ai/funds/xinshang-investment) — Series B